Evidence map›Paper›PMID 34211573›Full record

ArticleEvidence-based complementary and alternative medicine : eCAM2021

Anticancer Activity of

F Beheshti, A A Shabani, M R Akbari Eidgahi, P Kookhaei, M Vazirian, M Safavi

Open access · hybridAbstract read
In one paragraph

Article in Evidence-based complementary and alternative medicine : eCAM, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.0field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

F BeheshtiResearch Center of Biotechnology, Semnan University of Medical Sciences, Semnan 009823, Iran.ORCID https://orcid.org/0000-0003-2141-6278
A A ShabaniResearch Center of Biotechnology, Semnan University of Medical Sciences, Semnan 009823, Iran.ORCID https://orcid.org/0000-0002-5746-9980
M R Akbari EidgahiResearch Center of Biotechnology, Semnan University of Medical Sciences, Semnan 009823, Iran.ORCID https://orcid.org/0000-0002-4097-4876
P KookhaeiCancer Research Center, Semnan University of Medical Sciences, Semnan 009823, Iran.ORCID https://orcid.org/0000-0001-9322-107X
M VazirianDepartment of Pharmacognosy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran 009821, Iran.ORCID https://orcid.org/0000-0002-2080-5995
M SafaviDepartment of Biotechnology, Iranian Research Organization for Science and Technology, 13353-5111, Tehran 009821, Iran.ORCID https://orcid.org/0000-0003-0950-3141
Semnan University of Medical Sciences · IRIranian Research Organization for Science and Technology · IRTehran University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer is a leading cause of death and a vital health care challenge in the world. Hence, this work was conducted to determine the

Identifiers

PMID34211573
PMCPMC8205580
OpenAlexW3168142228

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.